Member Info for Trickymatters

I suspect it fell because the US market woke to a significant increase from Friday cop. They've taken profits and will now buy back. The share is volatile because the company needs funds but they're also concluding the consultation for national health insurance coverage in the US. The market is a massive 10 million people- those with diabetes 2 who have health insurance? At $950 that's worth the interest of any big pharma.

Https://www.nsmedicaldevices.com/news/renalytixai-astrazeneca-ckd/

Looks like you'll have to cut and paste the link. Sorry for that.

The RENX platform has come on a lot since then and is now targeting those with diabetes 2 to establish any kidney disease at an early stage, not just those with established chronic kidney disease. The company says the market is potentially 10 million US citizens.

Maybe someone on stocktwits could post the link there too. They seem to be operating without this information.

I've posted the link with the AZN agreement on Twitter. Anyone want it on here?

Yes, they've been collaborating on exactly this disease since August 21st 2020 when they signed an agreement to do so. Will post the link.

It's decision time at the end of this month about whether to extend this kidney test nationwide across US health insurers. The company are near the end of the formal consultation process. They got FDA approval last Summer and have already been picked up by the US government for US services. Check the RNS'.

Please don't engage with the troll guys. He's told us he's short. He's not got out in time the daft old brush.

It's going to multi-bag.

😀😁 This is what I call a good day! No sign of our shorters today😆

Brilliant news! GLA!

Maj you're acting like a real thick geezer. This company is 2 months away from getting national Medicare coverage for the whole of the US. AVACTA are 2 years away from finishing trials. This is the RENX board.

They won't need to become profitable. This will be sold to a big pharma within months of Medicare approval. Gilead Science or Pfizer or AstraZeneca or Johnson and Johnson will make them profitable. You should read the pharma press or the FT. Before you lose your shirt.

It's abundantly clear that the US wants this test. They are already buying up this stock.

The market cap is £40 million. The product is under a two month assessment process to get Medicare coverage for the whole of the US. It hasn't had that before so sales have been low. This is the fruition of many years of work and investment. What makes you think they won't be able to attract massive investment for a product worth hundreds of millions which will save billions? And save tens of thousands of lives.

My spell checker is turning capitals off😄 and the asterisk word was h o m o g e nous. Not a term of abuse LSE😄 It means we're not all the same. We will react differently.

think it ain't over till results come in. if we get a report on the debt first i suspect they won't have delivered on most of it. the leak yesterday showing an agreement from the iraqi government to pay well over $200 million is very positive. the market may well react badly initially though to nearly $400 million outstanding. depends how pis themselves respond really. we have a majority holding. but we are not ****geneous are we?

i think if that $200 million is reflected in the reporting it will reduce anxiety. and there could be more than that of course. if they do a raise we're going down in the short term.

but i also think results showing £6.6 billion revenues, a big boost from last year and more to come will turn it all around. best case scenario, they release the debt recovery report as part of results or simultaneously. gla.

I'm not saying they'll get absolute penetration. I think they'll get bought out within 6 months of getting insurance coverage from Medicare. A bigger fish will take care of fighting for market share. Who else has a test of this quality?

Yeah Maj. You know better than the US market for a product launch poised for the US 😄

I think some of the shorters can't read maybe? FDA approval was secured last Summer. This is much better than FDA approval. This is the process of getting coverage for the US health insurance policy and system. It's going great guns so far. Yesterday's news that the US government has approved RENX's kidney test for all of it's defence services bodes very well for the forthcoming meeting in early May to determine national US coverage. If signs of kidney disease were picked up earlier it can be prevented from developing. It will save US insurance agencies billions and save lives. The insurance agencies have a vested interest in adopting widespread usage of the test and so have the government. Any decent government has a vested interest in eliminating the development of kidney disease really, doesn't it?

The company thinks it is months away from achieving widespread adoption of this test.

Shorters are actually telling us that they are shorting. So their agenda is obvious. Maj is also a shorter- he's been around. I suspect these people lose a lot of money. They are really aggressive and they never properly engage in the discussion. A bunch of scammers. I'm in. I will buy more after the funding announcement if not before.

We might also hear about recommendations from yesterday's meeting before then. Every time another large, credible authority adopts the test it increases the likelihood of total coverage. So far, so very, very good.

A market of 10 million and an agreed price of $950.

Wonder what it's going to open at tomorrow.

Well we're doing well today anyway! I think I may regret my caution for my next buy😄 GLA! Glad I'm in for sure.

OBD raised at a premium only a few months ago. There's a serious appetite for acquisitions in the pharma sector with a lot of big pharma bearing the end of patents. Read the pharma press or read the FT.

I wasn't in AVACTA. I agree they're a long way from anything atm. The regulatory process is a long one. Then it still takes time to get where this company is now- getting on the US insurance policies. That's why they haven't sold much. But they're at the final hurdle- just a couple of months before the consultation process ends. Then we'll see widespread adoption.

Maj is a serial shorter obvs.

Timing is important in investing. You can wait until they've been adopted by Medicare with full coverage or you can make an educated guess that they will be on the not unreasonable assumption that since they already have FDA approval and are already engaged in the process for adoption by US insurers, that is a very serious possibility if not a certainty. Then it's game on. Everyone has debt in business. It's whether they can take care of that and offer a viable solution for a mass market that matters.

OBD raised at a premium a few months ago. I have just pointed out the massive difference between AVACTA and RENX in terms of regulatory approval and preparedness for the market. But I am also wary enough to consider that they won't raise at a premium. I will wait to buy more. Are you having trouble with your reading and comprehension Maj?

Bit of a dilemma whether to buy now or after the raise. They might raise at a premium. It does happen. If this gets further coverage for the US as a whole with a projected market of 10 million x $950 US dollars that's an absolute multi bagger. Obviously it will take time to get there but the decision to adopt is due after the consultation process ends in May. I think by then this will already have bagged at least once probably more. Another 6 months and it's getting bought out? When do you get the chance to get in at such a low price when they've already got FDA approval?

This kind of precision healthcare is going to be the future of healthcare. Preventative, saving money saving lives and ensuring a better quality of life.

Having said that watching the AVACTA debacle, I will wait until the raise before I buy more. But an interesting comparison. All that hype over AVACTA for a phase 1a treatment two years away at least- from the company's own reckoning and they've been late with everything, compared to a tried, tested, approved product already with early adoption by US insurance agencies including Medicare, now in consultation for mass adoption which RENX is offering. That's why this spiked a couple of weeks ago. The US market knows what this will be worth.

The level of resources from gas and oil implied for ORCA with most of the investment carried by Ping, Triangle et al is phenomenal. Waiting on just 1/3 licenses- 2 have been awarded. Over 18% of the Ping partnership owned by ORCA and 50% of the other 2 owned by ORCA. £3 million to follow on completion of due process from Ping and Shell approval to support ORCA's initial investment needs- relatively minimal after the deal agreed. A recent fund raise has hit the sp but really what's not to like. Read the whole RNS. They say they are confident that the Ping deal will be done by the end of March. Any day now the sp is going to march right up to the top of the hill. Quiet now but suddenly it won't be.